The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.
In the first of five stories on the battle to address skyrocketing drug prices in the U.S., <i>Institutional Investor</i> looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington.
